Drumakers likely to face tough times in second half

The prevailing view in the pharmaceutical industry is that the tough times will continue in the second half of this year because there is no immediate sign of a drug demand rebound.

Korean drugmakers are fighting an uphill battle on multiple fronts that is increasingly denting their bottom line. The firms are struggling to deplete increasing volumes of stocked drug products and fallout from...